Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban
نویسندگان
چکیده
Acute pulmonary embolism (PE), the most dangerous clinical manifestation of venous thromboembolism (VTE), represents a major threat for the health, the well-being, and occasionally the life of a large number of patients worldwide (1). However, more than 95 % of patients are haemodynamically stable at presentation and thus considered not to be at high risk of an adverse early outcome. Within this large group, the challenge for the clinician is to determine which patients are at truly low risk and may qualify for early discharge. Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban Rationale and design of the HoT-PE Trial
منابع مشابه
Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE Trial.
Pulmonary embolism (PE) is a potentially life-threatening acute cardiovascular syndrome. However, more than 95 % of patients are haemodynamically stable at presentation, and among them are patients at truly low risk who may qualify for immediate or early discharge. The Home Treatment of Pulmonary Embolism (HoT-PE) study is a prospective international multicentre single-arm phase 4 management (c...
متن کاملUse of rivaroxaban in an elderly patient with intermediate-low early mortality risk due to pulmonary embolism: a case report
INTRODUCTION Pulmonary embolism remains one of the leading causes of cardiovascular mortality. The standard treatment for pulmonary embolism is anticoagulant therapy using low molecular weight heparin, fondaparinux and a vitamin K antagonist, but a recent clinical trial showed that rivaroxaban, an oral factor Xa inhibitor, was as effective as standard therapy for the initial and long-term treat...
متن کاملPharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism
Patients with deep vein thrombosis or pulmonary embolism are recommended to receive anticoagulation for acute treatment and secondary prevention of venous thromboembolism (VTE). Fast-acting direct oral anticoagulants, with or without parenteral heparin, have the potential to replace vitamin K antagonists in this setting. Rivaroxaban, a direct Factor Xa inhibitor, is approved in the European Uni...
متن کاملRecent advances in the management of venous thromboembolism
Venous thromboembolism (VTE) is a spectrum of diseases that includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Anticoagulant treatment is the mainstay of therapy for VTE. Unfractionated heparin (UFH) or low molecular weight heparin (LMWH) followed by vitamin K antagonists have been the treatment of choice for most patients with VTE, with the aim to prevent thrombus extension or em...
متن کاملClinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation – patient considerations
The direct factor Xa inhibitor rivaroxaban was the first within the group of orally available direct factor Xa inhibitors to gain clinical approval for oral anticoagulation in patients with nonvalvular atrial fibrillation in 2011. The -xabans, as drugs from the group of oral direct factor Xa inhibitors are often referred to, comprise currently three drugs (apixaban, edoxaban, and rivaroxaban) w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2017